Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00028600 | Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 60 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 4, 2016 | clinicaltrials |
| NCT00053196 | Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer | completed | Phase 2 | 82 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 1, 2016 | clinicaltrials |
| NCT00578942 | Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath | completed | Phase 2 | 48 | David Rizzieri, MDOTHER | 1 | Jun 24, 2016 | clinicaltrials |
| NCT00540644 | Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 70 | Attaya SuvannasankhaOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT00861250 | Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT | completed | Phase 2 / Phase 3 | 47 | Tampere University HospitalOTHER | 1 | Jun 17, 2016 | clinicaltrials |
| NCT01079936 | Lenalidomide and High-Dose Melphalan | completed | Phase 1 / Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 6, 2016 | clinicaltrials |
| NCT01522872 | Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 98 | Threshold PharmaceuticalsINDUSTRY | 1 | Jun 2, 2016 | clinicaltrials |
| NCT01658904 | Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2016 | clinicaltrials |
| NCT01286077 | Velcade Consolidation Bone Study | completed | Phase 2 | 106 | Janssen-Cilag International NVINDUSTRY | 8 | May 30, 2016 | clinicaltrials |
| NCT01034553 | Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 26 | Mayo ClinicOTHER | 1 | May 25, 2016 | clinicaltrials |
| NCT01376401 | Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT00406978 | Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients(MPTD) | completed | Phase 1 / Phase 2 | 24 | Silvio AimeOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT00961467 | RMPT for Relapsed/Refractory Multiple Myeloma(RMPT) | completed | Phase 2 | 44 | Fondazione EMN Italy OnlusOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT01501370 | Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy(ZLd_Ld) | withdrawn | Phase 2 | 0 | Tiziana MarangonOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | terminated | Phase 1 / Phase 2 | 4 | Baylor College of MedicineOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT00833833 | MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 259 | Celgene CorporationINDUSTRY | 2 | Apr 27, 2016 | clinicaltrials |
| NCT02507479 | Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies | unknown | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT01023880 | Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy | terminated | Phase 1 / Phase 2 | 62 | CephalonINDUSTRY | 1 | Apr 11, 2016 | clinicaltrials |
| NCT02140840 | UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | Apr 7, 2016 | clinicaltrials |
| NCT01394354 | Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)(VBDD) | completed | Phase 1 / Phase 2 | 34 | University Hospital FreiburgOTHER | 1 | Apr 6, 2016 | clinicaltrials |
| NCT00615589 | Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen | terminated | Phase 2 | 22 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT01450215 | Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma | completed | Phase 2 | 62 | Karolinska University HospitalOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT00999830 | Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma(REMYKIR) | completed | Phase 2 | 27 | Innate PharmaINDUSTRY | 1 | Mar 24, 2016 | clinicaltrials |
| NCT01518153 | Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01541332 | Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 70 | OncotherapeuticsINDUSTRY | 1 | Mar 10, 2016 | clinicaltrials |
| NCT00618969 | Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors | completed | Phase 2 | 2 | University of ArizonaOTHER | 1 | Mar 3, 2016 | clinicaltrials |
| NCT00123773 | Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence | completed | Phase 2 | 1,075 | AHS Cancer Control AlbertaOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT00975975 | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | completed | Phase 2 | 17 | Indiana UniversityOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01352338 | Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)(REPEAT) | completed | Phase 1 / Phase 2 | 82 | UMC UtrechtOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01413568 | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 38 | Polyphor Ltd.INDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01094548 | Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy | completed | Phase 2 | 34 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Feb 22, 2016 | clinicaltrials |
| NCT01329289 | SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma | withdrawn | Phase 2 | 0 | University of PittsburghOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT01886976 | Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138(CART-138) | unknown | Phase 1 / Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT02624440 | Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma(SUTRICA) | unknown | Phase 2 | 300 | Henrik GregersenOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT00514371 | A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma(TIME-2) | completed | Phase 2 / Phase 3 | 22 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 7, 2015 | clinicaltrials |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | terminated | Phase 1 / Phase 2 | 3 | Singapore General HospitalOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT01521533 | NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma | completed | Phase 2 | 28 | TME Pharma AGINDUSTRY | 4 | Oct 6, 2015 | clinicaltrials |
| NCT01084837 | Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure(RENVEL) | completed | Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT00915408 | A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma(CRD) | completed | Phase 1 / Phase 2 | 32 | King's College Hospital NHS TrustOTHER | 1 | Sep 2, 2015 | clinicaltrials |
| NCT01085214 | AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2015 | clinicaltrials |
| NCT01812096 | Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China(MM) | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 18, 2015 | clinicaltrials |
| NCT02221479 | Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma | completed | Phase 2 | 14 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 4, 2015 | clinicaltrials |
| NCT00800059 | Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma(TMI-ASCT) | unknown | Phase 1 / Phase 2 | 27 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00131261 | Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma | completed | Phase 2 | 25 | Valerio TherapeuticsINDUSTRY | 4 | Jul 8, 2015 | clinicaltrials |
| NCT00431340 | A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma | terminated | Phase 2 | 4 | Valerio TherapeuticsINDUSTRY | 1 | Jul 8, 2015 | clinicaltrials |
| NCT02145715 | Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma(MUKsix) | unknown | Phase 1 / Phase 2 | 54 | Prof Jamie CavenaghOTHER | 1 | Jun 26, 2015 | clinicaltrials |
| NCT00083382 | Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide | completed | Phase 2 | 83 | University of ArkansasOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT01531998 | Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT00201695 | Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma | completed | Phase 2 | 12 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 10, 2015 | clinicaltrials |
| NCT02467010 | Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance(REMM) | completed | Phase 2 | 73 | University Medical Center GroningenOTHER | 1 | Jun 9, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Jul 4, 2016source: clinicaltrials